ISAD × WHO day

Preliminary Invited Participants and Draft Program

Purpose and General Structure of the Day 1.

The ISAD × WHO day will be held on Friday, 16 October 2026, immediately before the Rajka Symposium in Beijing. It will provide a structured forum to advance two closely linked ISAD priorities in atopic dermatitis: the development of an international Treat-to-Target consensus project and the continuation of ISAD–WHO-related work on access to care and essential medicines.

All invited participants listed below are invited for the full day. The day will have two distinct formats:

1. Morning session – closed to industry

This session will be devoted to the ISAD-led Treat-to-Target consensus project in atopic dermatitis. It will focus on scope, terminology, methodology, patient-centered outcomes, global feasibility, and the next steps toward Delphi consensus development.

2. Afternoon session – open to industry

This session will review ongoing ISAD–WHO-related projects, access-to-medicines priorities, and preparation for the 2027 WHO Essential Medicines List cycle. Industry participants will be invited separately and may contribute actively during the moderated discussions.

A short report from the closed morning Treat-to-Target workshop will be presented during the afternoon session. A further concise report from the day will also be presented at the main Rajka meeting.

Preliminary Invited Participants by Region of Origin 2.

ALL 79 IN-PERSON 59 REMOTELY 11 EXCUSED 2

Participant		Country Area	Affiliation	Role / Reason for invitation
WHO / Global Access
Lorenzo	MOJA	Switzerland	WHO Int. EML	2027 EML discussion / WHO interface
Europe
Maria	KINBERGER	Germany	Charité Berlin methodology team	Mapping / scoping review report
Alain	TAÏEB	France	ISAD	ISAD chair; afternoon and main-meeting report
Peter	SCHMID-GRENDELMEIER	Switzerland	ISAD	ISAD / allergy-dermatology interface
Andreas	WOLLENBERG	Germany	ISAD	Morning workshop rapporteur; T2T steering
Dirk-Jan	HIJNEN	The Netherlands	ISAD	AD expert / T2T discussion
Magdalena	TRZECIAK	Poland	ISAD	AD expert / European perspective
Mikael	ALSTERHOLM	Sweden	TSW group	TCS concern / TSW interface
Carsten	FLOHR	United Kingdom	GADA	GADA / ILDS leadership for EML project
Marie	LODÉN	Sweden	Pharmacist and dermatologist	EML consultant / emollient access discussion
Sébastien	BARBAROT	France	ISAD	Pediatric AD / European perspective
Christian	VESTERGAARD	Denmark	GADA	GADA / European perspective
Eurasia
Daria	FOMINA	Russia	Allergy	Eurasian perspective
Asia-Pacific
Saeko	NAKAJIMA	Japan	APADtf	Japanese perspective
Eung	CHOI	South Korea	IEC	Korean / Asian perspective
Sandipan	DHAR	India	ISAD, IEC, GADA Steering Committee	Asian AD guidelines task force
Maria Victoria	DIZON	Philippines		APADtf
Kathryn	GIBSON	Australia	Rheumatology PROMs	Patient-reported outcomes / measurement
Somesh	GUPTA	India		Indian perspective
Smita	JOSHI	Nepal	APADtf	Nepal / South Asian perspective
Ajith	KANNANGARA	Sri Lanka	APADtf	Sri Lankan perspective
Kyu Han	KIM	South Korea	ISAD, IEC	Korean / Asian AD perspective
JiHyun	LEE	South Korea	APADtf	Korean perspective
Dong Hun	LEE	South Korea	IEC	Korean AD perspective
Kin Fon	LEONG	Malaysia	APADtf	Malaysian perspective
Wei	LI	China	Dermatology	Chinese host-country perspective
Ashoka	LIYANAGE	Sri Lanka	Skin Sri Lanka	Australian / Asia-Pacific perspective
Lin	MA	China	ISAD, IEC	Co-Chair, Chinese host / pediatric dermatology
Wilsie	SALAS-WALINSUNDIN	Philippines	APADtf	Philippine perspective
John	SU	Australia	ISAD	Morning workshop rapporteur; pediatric AD
Fang	WANG	China	Dermatology	Chinese host-country perspective
Hua	WANG	China	GADA collaborator	Chinese host-country perspective
Li-Chuen	WONG	Australia	APADtf	Australian / Asia-Pacific perspective ; pediatric AD
Anousha	YAZDABADI	Australia	Dermatology	Australian / Asia-Pacific perspective
Francis	THIEN	Australia	Pulmonology	Non-dermatology T2T input
Abishek	DE	India	APADtf	Indian perspective
Middle East
Atlal	AL-LAFI	Kuwait		Gulf / Middle East perspective
Arti	NANDA	Kuwait	ISPD	Pediatric dermatology
Yousef	BINAMER	Saudi Arabia	IEC Associate	Gulf / Middle East perspective
Aisha	AL-ALI	Oman		Gulf / Middle East perspective
Africa
Uchechi	EZEM	Nigeria	ASDV	African perspective
Carol	HLELA	South Africa	ASDV	African perspective
Oludolapo	KATIBI	Nigeria / UK	ASDV	African perspective
Ines	LAHLOUEL	Tunisia	ASDV	African perspective
Ahmed	MANJRA	South Africa	ASDV	African perspective
Andile Alexia	MBANJWA	South Africa	ASDV	African perspective
Mariem	TABKA	Tunisia	ASDV	African perspective
Ousmane	FAYE	Mali / Tanzania	ISAD, GADA Collaborator	African AD / LMIC perspective
Boubacar	AHY DIATTA	Senegal	ASDV	African perspective
Antoinette	CHATEAU	South Africa	ASDV	African perspective
Olufolakemi	COLE	Nigeria	ASDV	African perspective
Mahira	EL-SAYED	Egypt	ASDV	African perspective
Perpetua	IBEKWE	Nigeria	ASDV	African perspective
Suretha	KANNENBERG	South Africa	ASDV	African perspective
Kayitesi	KAYITENKORE	Rwanda	ASDV	African perspective
Emmanuel	KOUOTOU	Cameroon	ASDV	African perspective
Fatimata	LY	Senegal	ASDV	African perspective
Gloria	MASENGA	RDTC / Tanzania	ISAD-GADA Fellow	African training / capacity building
Shimelis	NIGUSSE DONI	Ethiopia	ASDV	African perspective
Erereoghor	OTROFANOWEI	Nigeria	ISAD, ASDV, GADA Collaborator	African AD guidelines task force
Fahafahantsoa	RAPELANORO RABENJA	Madagascar	ISAD, GADA Steering Committee, ASDV	African perspective
Fandresena	SENDRASOA	Madagascar	ASDV	African perspective
Lydie	SEUDJIP NONO	République Démocratique du Congo	ASDV	African perspective
Emna	BAHLOUL	Tunisia	ASDV	African / MENA perspective
Amina	OUEDRAOGO	Burkina Faso	ASDV	African perspective
North America
Michele	RAMIEN	Canada	ISAD, IEC	Pediatric AD
Lawrence	EICHENFIELD	USA	IEC	IEC leadership
Peter	LIO	USA	IEC, ITSAN interface	TCS concern / TSW
Eric	SIMPSON	USA	IEC, ISAD	AD outcomes
South/Latin America
Roberto	TAKAOKA	Brazil	ISAD Vice-President	Patient-centered medicine
Javier	ARELLANO LORCA	Chile	ISAD	Latin American perspective

Patient and Advocacy Participation 3.

Seven patient representatives or advocacy participants are currently planned:

Participant		Country / area	Perspective
Jennifer	AUSTIN	Canada	GlobalSkin
Kelly	BARTA	USA	ITSAN / TSW concern; GADA collaborator
Kristin	BELLENSON	USA	National Eczema Association
Melanie	FUNK	Australia	Patient representative
Brandon	HU	Australia	Patient / clinician advocate
Tina	MESARIČ	Slovenia	Patient representative; GADA collaborator
Ursula	SOH	Singapore	Patient advocate
Tammi	SHIPOWICK	Canada	GlobalSkin; GADA collaborator

Their contribution will be central to both the morning Treat-to-Target session and the afternoon discussion on access, communication, safety concerns, and meaningful disease control.

Roles of ISAD, IEC, GADA, WHO, ILDS, and Industry 4.

ISAD

ISAD will convene the meeting and coordinate the overall scientific agenda. ISAD will lead the Treat-to-Target consensus project, patient-centered discussions, regional guideline links, and reporting to the main Rajka meeting.

IEC

IEC will be involved throughout the day, especially in the Treat-to-Target consensus development and in ensuring alignment with international AD expertise.

GADA

GADA will contribute to global epidemiology, disease burden, metrics, and implementation perspectives of the T2T project. Through Carsten Flohr, GADA will also provide the operational link with ILDS for the access-to-medicines project.

WHO

WHO via Lorenzo Moja will contribute to the discussion on essential medicines and access to care, particularly in relation to the 2027 WHO Essential Medicines List process.

ILDS

ILDS, via Carsten Flohr/GADA, will be in command of the main project for possible inclusion of methotrexate and dupilumab in the 2027 WHO Essential Medicines List cycle (expected submission in September 2027).

Industry

Industry participants will be invited separately for the afternoon session. They will not participate in the closed morning workshop. In the afternoon, they will not be limited to observer status and may contribute actively during moderated discussions.

Preliminary Program of the Day

Please note all timings are based on Beijing time zone.
➜ China Standard Time (CST) – UTC+08:00

	Morning Session ~Closed to the Industry
08:30 12:30	Treat-to-Target in Atopic Dermatitis: from concept to consensus methodology Rapporteurs: Andreas WOLLENBERG and John SU
08:30 09:00	Arrival and registration for closed workshop ISAD / local organizing team
09:00 09:10	Welcome and objectives of the ISAD × WHO day Alain TAÏEB, Lin MA, John SU
09:10 09:25	Why Treat-to-Target is needed in atopic dermatitis ISAD T2T steering group (ISAD-IEC, GADA)
09:25 09:45	Lessons from asthma, multidisciplinary care, and long-term control Frank THIEN (pulmonologist)
09:45 10:10	Patient-reported outcomes, patient-centered medicine, pediatric aspects, “meaningful” disease control Kathryn GIBSON (Rheumatologist); Li-Chuen WONG (Pediatric dermatologist); patient representatives
10:10 10:30	Coffee break
10:30 10:55	Mapping/Scoping review for the AD T2T consensus process Maria KINBERGER / Charité methodology team
10:55 11:20	Proposing candidate domains: signs, symptoms, sleep, quality of life, flares, treatment burden, safety concerns, and patient priorities ISAD / IEC / GADA contributors
11:20 11:50	Global feasibility: adapting targets across high-, middle-, and low-resource settings GADA, African and Asian guideline task force representatives
11:50 12:20	Roundtable: scope, terminology, Delphi structure, governance, and next steps ISAD, IEC, GADA, patients, methodologists
12:20 12:30	Rapporteurs’ summary and agreed points for afternoon report Andreas WOLLENBERG and John SU
12:30–13:30	Lunch
	Morning reporting: The morning output should include a concise set of agreed points on: The scope of the T2T consensus project; The domains to be considered in the Delphi process; The role of patient-centered outcomes and PROMs; The global feasibility of proposed targets; The governance and timeline for the next phases of the project.
	Afternoon Session ~Open to the Industry
13:30 18:00	ISAD–WHO projects, access to care, and the 2027 WHO Essential Medicines List perspective Rapporteurs: ---
13:30 13:40	Welcome to the open afternoon session ISAD / WHO / Lin MA (ISAD Beijing 2026 local host)
13:40 14:00	Short report from the closed morning T2T workshop Andreas WOLLENBERG, John SU, Alain TAÏEB
14:00 14:25	ISAD–WHO collaboration: progress since Melbourne and priorities for 2026–2027 ISAD / WHO contributors
14:25 15:00	Essential Medicines for atopic dermatitis: lessons from emollients and preparation for the next EML cycles Lorenzo MOJA, Marie LODÉN, ISAD access group
15:00 15:30	ILDS-led project for the next EML cycle: methotrexate and dupilumab Carsten FLOHR for ILDS/ ISAD, IEC and other contributors
15:30 15:50	Coffee break
15:50 16:20	Discussion on access to topical/systemic treatments in AD: evidence, affordability, and implementation challenges across settings All
16:20 16:45	Regional perspectives on AD care and access: Africa, Asia-Pacific, Middle East, and Latin America Erere OTROFANOWEI, Sandipan DHAR, Javier ARELLANO, Roberto TAKAOKA, Middle East representatives
16:45 17:10	Patient priorities, patient-centered medicine, safety concerns, access, and communication Roberto TAKAOKA, patient representatives and advocacies
17:10 17:35	Moderated discussion with industry participants: evidence generation, affordability, responsible access, and global AD care Open moderated discussion; industry contributors welcome
17:35 17:50	Summary of action points: T2T consensus, EML 2027, regional guidelines, and patient engagement Alain TAÏEB with session rapporteurs
17:50 18:00	Closing remarks and preparation of short report for the ISAD Beijing 2026 meeting Alain TAÏEB, Lin MA, John SU
	Afternoon and main-meeting reporting: Alain TAÏEB will report the key points at the main Rajka meeting, including a short report from the closed morning T2T workshop and the main conclusions from the afternoon session, as part of ISAD president’s annual report.

Expected outputs of the day 5.

The expected outputs of the ISAD × WHO day are:

1. A clear statement of the scope and next steps of the ISAD Treat-to-Target consensus project.
2. Agreement on the main domains to be considered in the Delphi process.
3. Integration of patient-centered medicine and patient-reported outcomes into the T2T framework.
4. A short internal report from the closed morning workshop.
5. A shared update on ISAD–WHO-related projects and access-to-care priorities.
6. 2027 EML strategy for AD, including the ILDS project on methotrexate and dupilumab, and projects for EML 2029
7. Regional input on implementation challenges in Africa, Asia-Pacific, the Middle East, and Latin America.
8. A structured discussion with industry participants on evidence generation, affordability, responsible access, and global AD care.
9. A concise report to be presented at the main Rajka meeting on Monday 19th (afternoon).

Points still to be completed 6.

1. Add the industry participant list when available.
2. Confirm final availability of all invited participants.
3. Confirm the final local Chinese host roles.